The recent appointment of Dr. Edith A. Perez as Chief Medical Officer of Cornerstone Specialty Network represents more than a simple executive hire. When a physician who spent decades at Mayo Clinic and led oncology strategy at Genentech chooses to join a private equity-backed platform, it signals something significant about the firm behind the investment.
That firm is Waud Capital Partners, and the appointment validates a healthcare investment thesis that founder Reeve Waud has been building for over three decades. The decision by Dr. Perez—a researcher whose work fundamentally changed breast cancer treatment—to join Provider Network Holdings, a Waud Capital portfolio company, demonstrates the magnetic pull of Waud’s healthcare consolidation strategy.
The Foundation of Healthcare Expertise
Reeve Waud launched Waud Capital Partners in 1993 as a solo operation in Lake Forest, Illinois. Rather than pursuing the typical private equity path of diversified investments across multiple industries, Waud made a calculated bet on healthcare specialization. This focus has produced remarkable results: the firm now manages approximately $4.6 billion in assets and has completed more than 480 investments since inception.
The depth of Waud’s healthcare expertise becomes clear when examining his track record. His most notable success story began in 2005 when he formed Acadia as a startup platform in behavioral health, providing growth capital and strategic guidance. Under WCP’s ownership, Acadia expanded through acquisitions and organic growth into a leading network of psychiatric and addiction treatment facilities. In just six years, Acadia grew to a scale that allowed it to go public in 2011. Today, Acadia operates over 260 facilities across 40 states and Puerto Rico, and Reeve Waud continues serving as Chairman of the company’s board.
The Provider Network Holdings Strategy
Dr. Perez’s appointment caps an ambitious 18-month period during which Waud Capital assembled Provider Network Holdings through the combination of four healthcare companies: Altus Biologics, Remedy GPO, Cornerstone Specialty Network, and Health Coalition Inc. This roll-up strategy created a platform supporting over 1,500 provider partners across 41 states, spanning oncology, neurology, rheumatology, and other specialty practices.
The scale and scope of Provider Network Holdings reflects lessons learned from the Acadia Healthcare experience. Rather than building a single-specialty network, Waud Capital created a multi-specialty platform that offers supply chain services, group purchasing, and pharmaceutical solutions for biologic drug needs. This approach provides the network effects and operational efficiencies that independent specialty practices struggle to achieve on their own.
Why Elite Talent Chooses Waud Platforms
Dr. Perez’s career trajectory—from Mayo Clinic Professor Emeritus to Genentech executive to Bolt Biotherapeutics Chief Medical Officer—demonstrates a pattern of choosing market-leading organizations. Her decision to join Cornerstone Specialty Network reflects confidence in Waud Capital’s ability to build and scale healthcare businesses.
The appointment creates a compelling combination: Dr. Perez brings three decades of clinical research experience and pharmaceutical industry expertise, while Provider Network Holdings offers the scale and resources needed to implement innovative patient care programs across a network of 1,500 providers. As Dr. Perez stated in the announcement, “I am honored to officially join Cornerstone Specialty Network, an organization I have seen evolve into a leader in community oncology, at such a pivotal time for specialty care. We look forward to utilizing novel tools to optimize patient care by developing collaborative, retrospective, and prospective data generation and insights, across the network.”
This appointment signals that Reeve Waud’s healthcare investment approach continues attracting the industry’s most respected leaders, positioning Waud Capital Partners for sustained growth in the specialty healthcare services sector.
Related: Waud Capital unveils latest growth-oriented buyout fund, targets $1bn
